Clinical Outcomes in Patients with Diabetes Mellitus Using a Medically Supervised Commercial Weight Reduction Program Compared to Standard Care in an Endocrine Specialty Clinic
Journal Title: Journal of Diabetes and Obesity - Year 2016, Vol 3, Issue 2
Abstract
Aims: To evaluate metabolic and anthropometric changes achieved and maintained by diabetic patients (pts) in a structured weight loss (WL) program vs usual care in an endocrine clinic (UCG). Materials and Methods: This retrospective comparison study examined 38 diabetic pts with BMI >25 undergoing the active weight loss phase of WL determined by patient goal weight and then followed for 6 months in weight maintenance phase (WM). Multiple endpoints were assessed at baseline including BMI and hemoglobin A1c (A1c). Endpoints were reassessed at 6 months in WM. The usual care group (UCG) was obtained through chart review of 26 diabetic pts with BMI > 25 in an endocrine specialty clinic who completed an education program including lifestyle counseling by a certified diabetic educator. Data were analyzed using ANCOVA and protected LSD, adjusting for age, gender, and baseline weight. Results: Patients showed a change in BMI at 6 months of -6.8 ± 0 (bsl 44 ± 8.4) and -0.7 ± 1.1 (bsl 35 ± 6.2) for HMR® pts and UCG, respectively (p < 0.05). HMR® pts had 13.4% ± 3 % WL vs 7.9% ± 4% in UCG p = 0.34). 6 month A1c was similar in HMR pts (7.5% ± 2; bsl 8.3 ± 1.9) and UCG (7.5% ± 2.3; bsl 9.8 ± 1.8). HMR® pts had a reduction of total medication usage of 28%, with at least one medication discontinued in 80% of pts, while the UCG had only 23% of pts with discontinuation of at least one medication (p < 0.05). Conclusions: Compared to CDE-led diabetic education emphasizing lifestyle change, pts in an intensive WL program utilizing weekly coaching, meal replacements, and exercise, had a significant decrease in BMI and achieved a similar A1c with reduction in medication requirements.
Authors and Affiliations
Ryan Kennedy
Keywords
Related Articles
- EP ID EP417844
- DOI 10.15436/2376-0494.16.839
- Views 103
- Downloads 0
Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus
Background: The maximum permissible dose of liraglutide, a GLP-1 receptor agonist, under the Japanese Heath Insurance system is 0.9 mg/day. We determined the effects of adding metformin to liraglutide therapy in Japanese...
Effect of Chromium(III) -Amino acid (1:3)Complexes on High Sucrose Induced Insulin Resistance, Lipid Abnormalities - Oxidative Stress in Male Sprague Dawley Rats
This study was carried out to assess the anti-hyperglycaemic effects if any of novel synthetic binary chromium (III)-amino acid complexes in a high sucrose (HS) induced insulin resistance (IR) and or impaired glucose tol...
Clinical Outcomes in Patients with Diabetes Mellitus Using a Medically Supervised Commercial Weight Reduction Program Compared to Standard Care in an Endocrine Specialty Clinic
Aims: To evaluate metabolic and anthropometric changes achieved and maintained by diabetic patients (pts) in a structured weight loss (WL) program vs usual care in an endocrine clinic (UCG). Materials and Methods: This r...
Diabetes Risk Factors for Chronic Kidney Patients
Diabetes Mellitus DM Chronic Kidney Disease CKD and Coronary Heart Disease CHD are in practice a complex medical status which are closely associated and generally coexist This article focuses the diabetes risk f...
Rapid Perioperative Changes in the Quantitative Properties of Plasma Lipases and Lipoproteins in Morbidly Obese Surgical Patients
Background: The impact of bariatric surgery on abnormalities in blood lipids and lipoprotein metabolism during the perioperative period has been poorly studied. Objective: We studied the impact of bariatric surgery on th...